The main goals of Ulcerative Colitis (UC) treatment are to both induce and maintain the
clinical and endoscopic remission of disease, reduce the incidence of complications such as …

Ulcerative colitis (UC) is a chronic relapsing disorder of the colonic tract, characterized by a
dysregulated innate and adaptive immune response to gut microbiota that contributes to the …

This guideline is the second European Crohn's and Colitis Organisation [ECCO] evidence-
based consensus on inflammatory bowel disease [IBD] and malignancy, and is an update …

Background Real‐world data on clinical outcomes of ustekinumab in ulcerative colitis are
lacking. Objective To assess short‐and long‐term clinical outcomes of ustekinumab in …

Anti-tumor necrosis factor (anti-TNF) therapy has been successfully used as first-line
biologic treatment for moderate-to-severe inflammatory bowel disease (IBD), in both “step …

Simple Summary Inflammatory Bowel Diseases (IBDs) are increasingly prevalent
pathologies due to the rise in incidence in some geographic areas and the improvement in …

Inflammatory bowel diseases (IBD) encompass two main entities including ulcerative colitis
and Crohn's disease. Although having a common global pathophysiological mechanism …

Background Evidence on real‐world outcomes of ustekinumab for ulcerative colitis (UC)
patients is needed. Aims To summarise evidence on the real‐world outcomes of …

Background Efficacy and safety of ustekinumab for the treatment of ulcerative colitis (UC)
has been demonstrated in clinical trials, but few real-world data are available so far. The aim …

Simple Summary Crohn's disease (CD) and ulcerative colitis (UC) are chronic inflammatory
bowel diseases that affect the gut and extraintestinal organs. Preliminary evidence has …